XCUR

Exicure, Inc.

$1.08

21.31%
SectorHealthcareIndustryBiotechnologyCountryUnited States
OverviewAI BriefChartFinancialsExposureFilingsScoresNewsAnalystsInsidersOwnership

Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

Source: Yahoo Finance
Q-Score28/ 100
Market Cap$7.1M
P/E—
Dividend Yield0.00%
52-Week Range—
Next Earnings—
Analysts—
Beta0.34
AI summary

Price & performance

1M+2.9%
3M-21.2%
YTD-80.6%
1Y-72.1%
52-week range—
Beta0.34
Full chart and returns against a benchmark

Q-Score

28/ 100

Quality against peers; 50 is the peer median.

Growth35
Risk32
Performance60
Valuation18
Profitability16
Leverage19
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue—
Net income-$4.9M
Net margin—
Historical fundamentals

Red flags in filings

5active red flags
Going-concern doubtMar 25, 2026
Material weakness in controlsMar 25, 2026
Late filing noticeMay 15, 2026
Filings, findings and the timeline

Revenue exposure

0%of revenue from outside the US
United States100%
Regions, segments, customers and suppliers

Valuation

XCURIndustryP/E—89.69P/S—11.88EV/EBITDA—67.10P/B7.246.22PEG—4.02
Dividend yield0.00%
Every valuation metric